With its ability to overcome constraints related to eye motion artefacts, its true volumetric imaging capabilities, and its micron-level accuracy, HP-OCTTM is clearing the way for important new research opportunities in eye health and beyond.
As the first of its kind in the world, HP-OCTTM is an exciting next generation technology that has the opportunity to elevate clinical studies and trials and give both researchers and specialist practitioners more opportunities to improve health outcomes. The Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting held in Denver, Colorado earlier this year was the perfect opportunity to demonstrate this enormous potential and provide researchers a chance to test out the technology and provide their feedback.
As the Association’s first in-person meeting in three years, the event drew a strong audience from all over the world. We were thrilled by the positive response and the enthused feedback we received during and after the event about the technology’s potential use in future research projects. Notable points of discussions were HP-OCTTM being specifically beneficial for studies relating to:
- Axial length and retinal shape
- Myopia progression
- Volumetric retinal scans
- Choroidal imaging
- Epithelium mapping in keratoconus
Cylite CEO Kylee Hall said, “ARVO 2022 was a huge success for Cylite. To be able to showcase the HP-OCTTM with the new Focus software was hugely significant for the growth of the business, and moved us into the next phase of our journey. What was equally exciting was connecting in-person with researchers and hearing their thoughts on the technology as well as the important research and developments being made in eye and vision research.”
How researchers are already utilising HP-OCTTM
HP-OCTTM has been involved in a number of research projects as part of the development and pre-launch phase. Some of the earliest research projects to use the HP-OCTTM have been carried out by two of the world’s most respected research and educational institutions. Two of these were presented at the recent ARVO 2022, and the third at another ARVO event in 2021.
Jules Stein Eye Institute, UCLA
Associate Professor Edmund Tsui and Ms Nina Cherian from UCLA presented a research study entitled ‘Comparison of a novel hyper-parallel optical coherence tomography biometer with a swept source OCT biometer in patients with cataracts’. In this study, the HP-OCTTM was compared with the Argos (Santec Corporation, Komaki, Japan) swept-source OCT biometer with the purpose of comparing biometry measurements in patients with mature cataracts. Read more here.
“This study was a great opportunity for us to compared the HP-OCT to a commercially available swept-source biometer and it was very pleasing to see how closely correlated axial length, mean keratometry and central corneal thickness were in particular”, stated Cylite.
Stanford University
At ARVO 2022, Stanford’s Associate Professor Alfredo Dubra and optics PhD candidate Ms Grayce Huang presented their research titled ‘Retinal magnification factors derived from refraction-corrected optical biometry’. The research utilised the unique capabilities of the HP-OCTTM to quantify the anterior and posterior surfaces of the cornea and crystalline lens, as well as the distances between each surface, and then used ray tracing to take into account the magnification of individual eyes. This allowed the researchers to more confidently describe the proportions of the retina of each individual eye, which could be important for the measurement of retinal structures using OCT. Read more here.
Jules Stein Eye Institute, UCLA
Presented at ARVO’s Imaging of the Eye conference in 2021 was UCLA’s ‘Hyperparallel optical coherence tomography imaging of herpes zoster stromal keratitis‘ research. HP-OCTTM was used to capture volumetric images of the entire anterior segment in one scan and accurately evaluate structural images of the cornea. Images were obtained in a patient with herpes zoster stromal keratitis during an acute episode, and then again after treatment to assess efficacy of treatment and identify any other issues. A single scan of the cornea showed multiple areas of anterior stromal involvement; this enabled objective follow-ups to monitor corneal findings and capture high-quality images. Read more here.
